5Vote!
Philadelphia Inquirer (Free subscription) | 04/23/2009
The struggling economy will cost pharmaceutical companies $15 billion in lost sales this year, the research firm IMS Health Inc. said yesterday.
3Vote!
euronews24 (Free subscription) | 03/19/2009
NEW YORK - Sales growth of prescription drugs in the U.S. slowed for the second straight year, with the economic downturn playing a key role, according to IMS Health Inc. Market research firm IMS cites lower demand for less-expensive generic drugs, ...
5Vote!
San Fransisco Chronicle (Free subscription) | 03/19/2009
Sales growth of prescription drugs in the U.S. slowed for the second straight year, with the economic downturn playing a key role, according to IMS Health Inc. Market research firm IMS cites lower demand for less-expensive generic drugs, lagging new product...
5Vote!
The Washington Times (Free subscription) | 03/19/2009
Sales growth of prescription drugs in the U.S. slowed for the second straight year, with the economic downturn playing a key role, according to IMS Health Inc.
5Vote!
Seattle Times (Free subscription) | 03/19/2009
Sales growth of prescription drugs in the U.S. slowed for the second straight year, with the economic downturn playing a key role, according to IMS Health Inc.
5Vote!
Seattle Post-Intelligencer (Free subscription) | 03/19/2009
NEW YORK -- Sales growth of prescription drugs in the U.S. slowed for the second straight year, with the economic downturn playing a key role, according to IMS Health Inc.
5Vote!
Seattle Times (Free subscription) | 03/13/2009
David Carlucci, the chief executive of IMS Health Inc., received a compensation package worth $5.9 million in 2008, down 21 percent from the year before, according to an Associated Press calculation of figures disclosed in a regulatory filing made late Wednesday.
5Vote!
San Fransisco Chronicle (Free subscription) | 03/13/2009
David Carlucci, the chief executive of IMS Health Inc., received a compensation package worth $5.9 million in 2008, down 21 percent from the year before, according to an Associated Press calculation of figures disclosed in a regulatory filing made late...
5Vote!
Seattle Post-Intelligencer (Free subscription) | 03/13/2009
NEW YORK -- David Carlucci, the chief executive of IMS Health Inc., received a compensation package worth $5.9 million in 2008, down 21 percent from the year before, according to an Associated Press calculation of figures disclosed in a regulatory filing made late Wednesday.
5Vote!
Indy Star (Free subscription) | 02/15/2009
It had all the glow of a future blockbuster. When Byetta hit the market four years ago, diabetes patients raved over the drug's ability to help them control blood sugar while curbing their appetite and allowing them to lose weight.
5Vote!
Business Wire (Free subscription) | 02/12/2009
NORWALK, Conn.--(BUSINESS WIRE)--The Board of Directors of IMS Health (NYSE: RX) on February 10, 2009 declared a regular first-quarter 2009 dividend of $0.03 per share, payable on March 27, 2009 to shareholders of
1Vote!
GuruFocus Updates (Free subscription) | 02/12/2009
John Keeley 's flagship fund - Keeley Smallcap Fund - lost 40% in 2008, but he still outperformed the benchmarks during the past 5- and 10-year period by wide margins. He thinks that restructuring in the health care sector evolved recently which presented a few appealing opportunities. These are his buys and sells during the fourth quarter. John Keeley buys AmerisourceBergen Corp., IMS Health Inc.,...
1Vote!
Deutsche Welle: DW-WORLD.DE (Free subscription) | 02/12/2009
German pharmaceuticals company Bayer Schering Pharma has announced plans to invest 100 million euros (129 million dollars) over the next five years to open an R&D center in Beijing.
3Vote!
Daily News Analysis (Free subscription) | 02/12/2009
Pharma player Ranbaxy will have to fight it out with four others in the market.
Videos